Bromazine
From Wikipedia, the free encyclopedia
 |
|
|
Bromazine
|
|
| Systematic (IUPAC) name | |
| 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine | |
| Identifiers | |
| CAS number | 1808-12-4 (hydrochloride) |
| ATC code | R06 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H20BrNO |
| Mol. mass | 334.251 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding | 96% |
| Metabolism | Mostly hepatic (CYP-mediated), also renal |
| Half life | 1 to 4 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Bromazine (INN, also known as bromodiphenhydramine) is an antihistamine. It is a brominated derivative of diphenhydramine. The medicinal preparation of the hydrochloride has the brand name Ambrodyl
|
|||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
